Elanco Animal Health Incorporated $ELAN Stake Lowered by Private Management Group Inc.

Private Management Group Inc. reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 12.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 592,242 shares of the company’s stock after selling 86,075 shares during the period. Private Management Group Inc.’s holdings in Elanco Animal Health were worth $13,260,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. BlackRock Inc. purchased a new position in Elanco Animal Health in the second quarter valued at about $1,202,198,000. Primecap Management Co. CA acquired a new position in Elanco Animal Health in the 2nd quarter worth about $1,118,402,000. State Street Corp raised its stake in shares of Elanco Animal Health by 4.7% during the 2nd quarter. State Street Corp now owns 16,063,046 shares of the company’s stock worth $395,312,000 after purchasing an additional 726,567 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Elanco Animal Health during the 2nd quarter worth about $205,636,000. Finally, Sei Investments Co. raised its stake in shares of Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after purchasing an additional 4,975,721 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Elanco Animal Health

In other news, insider Timothy Bettington sold 4,350 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the completion of the transaction, the insider directly owned 138,911 shares of the company’s stock, valued at approximately $3,194,953. This trade represents a 3.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lawrence Kurzius bought 40,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the transaction, the director owned 188,647 shares in the company, valued at $4,414,339.80. This represents a 26.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 48,998 shares of company stock valued at $1,139,373 over the last quarter. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and cut their price objective for the company from $31.00 to $24.00 in a research report on Tuesday, October 20th. JPMorgan Chase & Co. lifted their target price on shares of Elanco Animal Health from $33.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Morgan Stanley reduced their target price on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average target price of $29.75.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: JPMorgan raised its price target to $35 from $33 and reiterated an Overweight rating, implying about 30.5% upside from the cited $26.82 share price. JPMorgan price-target update
• Positive Sentiment: Elanco’s Q3 results topped consensus: earnings were $0.27 per share versus $0.20 expected, while revenue reached $1.27 billion versus $1.21 billion expected and grew 11.3% year over year. The company also reported 9% organic constant-currency revenue growth and reduced gross debt by $216 million, supporting the growth and balance-sheet outlook. Three takeaways for long-term investors
• Positive Sentiment: A consumer survey found pet health is among the expenses owners are least willing to cut, a potentially supportive demand signal for Elanco’s animal-health products. Survey on pet-health spending
• Neutral Sentiment: Elanco presented at the UBS Global Healthcare Conference, but the supplied report does not detail new guidance or material announcements from the presentation. UBS conference transcript
• Neutral Sentiment: News of a new chief people officer is a management update; no direct financial or operational impact was specified. Elanco and animal-health industry updates

Elanco Animal Health Trading Up 4.2%

Shares of NYSE:ELAN opened at $26.82 on Tuesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The stock’s 50-day moving average is $23.18 and its 200-day moving average is $23.84. The company has a market cap of $13.40 billion, a P/E ratio of -89.41, a P/E/G ratio of 2.25 and a beta of 1.73. Elanco Animal Health Incorporated has a 52-week low of $19.40 and a 52-week high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.07. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the business earned $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.